Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with renal cell carcinoma (RCC).

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for oncologists, physician associates/physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review clinical data and consensus guideline recommendations on systemic treatment approaches for patients with operable, advanced, or metastatic RCC
  • Identify patients with RCC most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Plan evidence-based and expert recommended therapeutic sequencing strategies for patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC
  • Select patients with RCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
Additional information

Supported by educational grants from:

  • AVEO Oncology
  • Eisai Inc.
  • Pfizer Inc.

Supported by a medical education grant from:

  • Exelixis, Inc.

Supported by an independent educational grant from:

  • Merck & Co., Inc.
Course summary
Available credit: 
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
Course opens: 
Course expires: 

Katy E. Beckermann, MD, PhD
Vanderbilt-Ingram Cancer Center

Naomi B. Haas, MD
Abramson Cancer Center at the University of Pennsylvania

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Katy E. Beckermann, MD, PhD
Aravive: Consulting Fee
AVEO: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
Exelixis: Consulting Fee
Seagen: Consulting Fee

Naomi B. Haas, MD
AVEO: Consulting Fee
Eisai: Consulting Fee
Merck: Consulting Fee
Roche Genentech: Consulting Fee

Eric Jonasch, MD
Aravive: Consulting Fee
Arrowhead: Grant/Research Support
Avevo: Consulting Fee
Eisai: Consulting Fee
Exelixis: Consulting Fee
Merck: Consulting Fee; Grant/Research Support
NiKang: Consulting Fee; Grant/Research Support
Novartis: Consulting Fee; Grant/Research Support
Takeda: Consulting Fee

NCCN and CCO Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings. 


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 2.0 contact hours.

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-22-089-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until July 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing